From Hypothesis-Driven to Hypothesis-Free: The Future of Dx with Brad Murray
This week on Diagnosing Dx, I’m joined by Bradley Murray, CEO and co-founder of Delve Bio. Bradley shares his journey from academic research, success as a biotech startup, investment into life sciences and onto entrepreneurship, andhow those experiences shaped his approach to building diagnostics that put patients first.
We dive into why execution, not just vision is critical for survival in today’s diagnostics market, how Delve is transforming infectious disease testing through metagenomic sequencing, and what it takes to scale a company that’s tackling some of healthcare’s toughest…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.